Stellantis stock rating downgraded by BofA on weak European EV position

BofA Securities downgraded Stellantis NV (STLA) from Buy to Neutral, significantly reducing its price target to EUR10.00 from EUR16.00. This re-rating reflects BofA's lowered estimates and concerns over Stellantis's European operations, particularly its battery electric vehicle (BEV) positioning amidst rising competition, and an anticipation of weak first and second-half results. The downgrade follows a substantial year-to-date share decline for the automaker.

Analysis

BofA Securities has downgraded Stellantis NV (STLA) to Neutral from Buy, coupled with a material reduction in its price target to EUR10.00 from EUR16.00. This action is contextualized by the stock's significant underperformance, having declined approximately 30% year-to-date and 55% since its Capital Markets Day in summer 2024. The core of BofA's bearish thesis rests on concerns regarding Stellantis's European operations, specifically its competitive positioning in the battery electric vehicle (BEV) market, which is facing intensifying competition. While the firm acknowledges potential for a U.S. market recovery driven by upcoming model launches, this is overshadowed by a broader expectation of weak financial results for both the first and second half of the year and a perceived lack of near-term catalysts. The revised price target reflects BofA's lowered earnings estimates and a valuation roll-forward to FY27, indicating a more cautious long-term outlook.

Key Decisions for Investors

• Investors should exercise caution, as the downgrade and significant price target cut from a major institution signal a deterioration in the company's near-to-medium-term outlook.
• Monitor upcoming earnings reports for weakness in European sales and margins, as this is the primary driver of BofA's revised, more pessimistic forecast.
• The contrast between a potentially recovering U.S. market and a struggling European EV segment suggests a thesis based on a U.S. turnaround carries significant geographic and product-specific risk.
• Given the stated lack of catalysts and expectation of weak H1/H2 results, holding positions in anticipation of a near-term recovery may be a high-risk strategy.